AMGN Form 4: Charles M. Holley RSUs Vest, Converted to Shares
Rhea-AI Filing Summary
On 08/08/2025 Amgen director Charles M. Holley reported the immediate vesting of restricted stock units (RSUs) granted under Amgen's Director Incentive Program. The vested RSUs were converted to common stock on a one-for-one basis and recorded as an acquisition (transaction code A) with a reported price of $0.
Following the reported transaction Holley beneficially owns 11,469.6259 shares directly and 1,260 shares indirectly through the Holley Family Trust. The filing also shows 1,294 Dividend Equivalents credited to vested but deferred RSUs, which are payable in shares one-for-one with cash for any fractional share amounts.
Positive
- Vested RSUs were converted to common stock on a one-for-one basis under the Director Incentive Program
- Beneficial ownership is quantified: 11,469.6259 shares direct and 1,260 shares indirect via Holley Family Trust
- 1,294 Dividend Equivalents were credited and will be paid in shares (with cash for fractional amounts)
Negative
- None.
Insights
TL;DR: Routine director RSU vesting converted to stock; disclosed direct and indirect holdings but no cash purchase.
The Form 4 documents immediate vesting of RSUs for a company director and conversion to common shares with a reported price of $0, indicating issuance on vesting rather than an open-market purchase. The filing quantifies beneficial ownership after the transaction as 11,469.6259 shares direct and 1,260 shares indirect. This is a standard director compensation event and, based on the data in the filing alone, does not indicate a material capital change for Amgen.
TL;DR: Disclosure aligns with routine director equity compensation practices and mentions dividend equivalents and deferral options.
The explanation clarifies the award was under the Amgen 2009 Director Incentive Program and that vested RSUs are paid in shares one-to-one; directors may elect deferral. The filing also notes 1,294 Dividend Equivalents credited to vested but deferred RSUs, paid in shares along with cash for fractional shares. The report is a standard Section 16 disclosure of compensation-related share issuance.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 147.452 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. These shares include 1,294 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.